Edition:
India

Reata Says Kyowa Hakko Kirin Initiated Ayame, A Phase 3 Trial Of Bardoxolone Methyl For The Treatment Of Diabetic Kidney Disease


Monday, 4 Jun 2018 

June 4 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES THAT KYOWA HAKKO KIRIN INITIATED AYAME, A PHASE 3 TRIAL OF BARDOXOLONE METHYL FOR THE TREATMENT OF DIABETIC KIDNEY DISEASE.REATA PHARMACEUTICALS INC - ESTIMATED PHASE 3 STUDY COMPLETION DATE IS MARCH 2022. 

Company Quote

56.77
-1.02 -1.77%
12:10am IST